David Gardner Mutch, MD
Ira and Judith Gall Prof. of OB/GYN, Dir. Div. of Gyn. Onc.
Washington University School of Medicine
4911 Barnes Hospital Plaza
NA
St. Louis,
MO
USA
63110
Papers:
6
Clinical implications for MSI, MLH1 methylation analysis and IHC in Lynch screening for endometrial cancer patients: an analysis of 940 endometrioid endometrial cancer cases from the GOG0210 study
45
Clinicopathologic features associated with defective DNA mismatch repair (MMR): a GOG0210 cohort study of 1041 endometrioid endometrial cancer cases
84
Universal screening for Lynch syndrome in endometrial cancer results in increased acceptance of genetic counseling and testing
105
Comparison of dose-dense and every-3-week taxane in the neoadjuvant treatment of ovarian, fallopian tube, and primary peritoneal cancer
144
Relationship between Body Mass Index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project
148
Cell-based therapy in ovarian cancer: improved adenoviral transduction strategy of human mesenchymal stem cells as tumor-homing drug factories
158
Mesothelin-derived peptide vaccination leads to survival advantage in epithelial ovarian cancer mouse model
164
Outcomes for partial metabolic response on post therapy positron emission tomography for cervical cancer: role of surgical intervention
245
Gyn/Onc partnership with sarcoma center yields superior clinical trial enrollments for uterine leiomyosarcoma patients
332
Antibody fragments targeting the tumor marker mesothelin selectively deliver TRAIL therapeutics and cause efficient ovarian cancer cell death
387
Awareness of the association between obesity and perioperative risk among newly diagnosed endometrial cancer patients
511
Unveiling novel mutations in the DNA-binding domain of FOXA2 in endometrioid endometrial cancers